Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma

Ali Nabavizadeh; Stephen J Bagley

doi:10.1158/1078-0432.CCR-23-3027

Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma

Clin Cancer Res. 2024 Jan 17;30(2):255-256. doi: 10.1158/1078-0432.CCR-23-3027.

Authors

Ali Nabavizadeh¹, Stephen J Bagley²

Affiliations

¹ Department of Radiology, Hospital of the University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 37982809
DOI: 10.1158/1078-0432.CCR-23-3027

Abstract

In this CCR Translations, we discuss pharmacologic ascorbate as a novel therapeutic for glioblastoma (GBM). Aberrant iron metabolism in GBM can be assessed noninvasively by MRI and exploited to potentially improve the efficacy of chemoradiotherapy. We contextualize the study's results and discuss the next steps to further develop this paradigm. See related article by Petronek et al., p. 283.

Publication types

Comment

MeSH terms

Antineoplastic Agents* / therapeutic use
Brain Neoplasms* / drug therapy
Brain Neoplasms* / metabolism
Chemoradiotherapy / methods
Glioblastoma* / drug therapy
Glioblastoma* / metabolism
Humans
Iron

Substances

Antineoplastic Agents
Iron